Form 4: Lexeo CTO Sells Shares for Tax Obligations
Insider Transaction Report
Lexeo Therapeutics' Chief Technical Officer, Jose Manuel Otero, sold 2,848 shares of common stock to cover tax obligations related to restricted stock units.
Summary
- Jose Manuel Otero, Chief Technical Officer of Lexeo Therapeutics, Inc. (LXEO), reported a transaction on August 18, 2025.
- The transaction involved the sale of 2,848 shares of Lexeo Therapeutics common stock.
- The shares were sold at a price of $4.668 per share.
- The purpose of the sale was to cover tax obligations arising from the release of restricted stock units (RSUs).
- Following this transaction, Mr. Otero beneficially owns 60,372 shares, which includes 49,687 restricted stock units (RSUs).
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, the stated reason (tax obligations on RSU release) is common and generally not viewed as a negative signal about the company's prospects. It's a routine event for executives receiving equity compensation.
Negatives
- An insider sale, even for tax purposes, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Management Comments
- The sale represents a transaction to cover tax obligations on the release of restricted stock units (RSUs).
Industry Context
This is a routine insider transaction filing (Form 4) and does not provide information related to broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: A very minor dilution effect from the sale of shares, but the transaction size is small relative to the company's overall outstanding shares. The tax-related reason mitigates concerns about insider confidence.
- Employees: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 08/18/2025 | Date of transaction for the sale of common stock. |
| 08/20/2025 | Date the Form 4 was signed by the Attorney-in-Fact. |
Keywords
Lexeo Therapeutics, LXEO, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, RSUs, Jose Manuel Otero, Chief Technical Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.